For instance, S1PR3 agonists have been shown to enhance bone formation by promoting osteoblast differentiation, whereas S1PR2 antagonists may suppress bone resorption, offering targeted strategies for osteoporosis management (75). Here, S1PR2 is linked to osteoporosis.